Perhaps Mr. Kellog felt he was simply refining the focus of the previously-articulated rationale for withdrawing 2011 guidance, in the wake of the Vorapaxar disappointment, and the looming J&J arbitration outcome, but the below certainly sounds different than the sound-bites offered a month and a half ago — that earlier rationale included industry pressures from European austerity measures and the U.S. health overhaul law.
From Reuters coverage of the Citi event in Manhattan this morning:
“The most important element is we wanted the freedom and flexibility to invest,” Kellogg told the Citi global healthcare investor conference. . . .
Other than this, above (which I knew the wires would cover), I heard nothing particularly new, or material of note — so I did not put up a live-blog entry.
Anyone out there with different insights?